CenTNF chimeric anti-TNF monoclonal antibody data

CNTO (Malvern, Penn.) said its U.K. Phase II trial in 73 patients has been completed and the results confirm the findings of an open-label study published in December. That study found the agent to be safe and to lessen symptoms, as well as to improve certain laboratory values indicative of the disease. No allergic reactions were found in the first trial, despite repeated administration.

Doses in the Phase II study were 1mg/kg and 10 mg/kg. Beyond saying the results were significant, CNTO isn't releasing further information until the data are presented and published. ...